The SE AETCSoutheast AIDS Education & Training Center
The Southeast AIDS Education and Training Center serves the HIV/AIDS Educational Needs of Health Care Providers in Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee.
The AETC Program has been a cornerstone of HRSA’s HIV/AIDS program for over two decades. The mission of the AIDS Education and Training Centers Program (AETC) is to increase the number of health care providers who are effectively educated and motivated to counsel, diagnose, treat, and medically manage people with HIV disease, and to help prevent high-risk behaviors that lead to HIV transmission.
This mission is obtained through implementation of multidisciplinary education and training programs for health care providers in the prevention and treatment of HIV/AIDS. Overall, the AETC Program is charged with increasing the knowledge, skills and behaviors of providers and organizations to be able to provide quality care and increase access to care.
The AETC Program aligns with the goals of the National HIV/AIDS Strategy (NHAS):
- Reduce new HIV infections;
- Increase access to care and improve health outcomes for people living with HIV; and
- Reduce HIV-related health disparities.
As we move forward we renew our commitment to improving the quality of our data and using it, in turn, to continue to improve the quality of HIV care that we are able to provide. And better care means better health and better lives for people living with HIV/AIDS.
Sign up for our e-mail newsletter:
Register for our next Webcast Wednesday
In 2010, the region had the highest rates of HIV and AIDS diagnoses in the country as well as the highest number of people living with HIV compared to all other regions. Individuals diagnosed with HIV in the South fare poorly compared to other areas of the country. Three-year HIV survival rates were the lowest in the country. In addition, the SE AETC region has higher rates of HIV and AIDS diagnoses in women, blacks, and Hispanics, as compared with the rest of the country.
The geographical area served by SE AETC comprises diverse populations of PLWHA and HIV care providers faced with unique challenges and barriers to care. As the national HIV/AIDS epidemic has evolved, clinical care has moved from crisis-based, specialty interventions to long-term chronic disease management. As virologic control became the expected goal, poverty, stigma and access to expert care became critical factors that determined successful outcomes for People Living with HIV/AIDS (PLWHA).
The PLWHA seeking care in a small clinic in the rural South may have to deal with geographic and social isolation, stigma, religious intolerance, limited healthcare resources and extreme poverty while the PLWHA seen in a large urban HIV treatment center may be faced with overburdened staff, homelessness, substance abuse, and mental health issues.
The clinician treating these complicated, underinsured patients often has to focus on metabolic disease as well as monitoring and managing the patient’s HIV infection. Problems with polypharmacy, adherence, medication access and tolerability of treatment regimens are all magnified in these patients who may be traveling long distances to see their providers.
HIV Care Continuum National Statistics
Received Medical Care
We’re Here to Help
Health care providers, including HIV specialists and primary care providers, need access to the knowledge and skills necessary to ensure that HIV care is consistent with established guidelines and reflects current research. As the treatment of HIV disease is not restricted to any one medical specialty, various health care professionals serve as HIV experts. Ongoing continuing education is required for HIV expertise, regardless of specialty training.
The AETC Program and its multiple components work together and serve as a comprehensive training and educational resource for health care providers in the treatment and prevention of HIV/AIDS.
Latest News & Updates
Source: NEJM Journal Watch A dose-finding study revealed impressive efficacy and safety. Combination antiretroviral therapy (ART) is far simpler than it was 2 decades ago, and it entails many fewer adverse effects. Even so, some patients do not adhere to daily...read more
Hepatitis C Consultation Services (844) 437-4636 | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical advice to support clinicians managing patients with hepatitis C (HCV)...read more
Source: NEJM Journal Watch The increasing use of HIV integrase inhibitors in antiretroviral therapy has decreased the incidence of new antiretroviral drug resistance in real-world clinic situations. When resistance did emerge, classic risk factors like poor adherence...read more
Source: NEJM Journal Watch Compared with the general population or with HIV-uninfected high-risk persons, those living with HIV have higher lifetime risk for cardiovascular disease, which should be addressed as part of HIV management. Persons living with HIV, even...read more
Source: hiv.gov Results From Early-Stage NIH-Funded Trial Support Further Development of Candidate Vaccines Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses...read more
Source: hiv.gov Participants in NIH-Supported Study Apprehensive about Combining HIV Medications and Hormones Transgender women—people whose birth certificates indicate or once indicated male sex but who identify as women—are at high risk of HIV acquisition, and thus...read more
Source: hiv.gov The National Institutes of Health has launched a study to determine the potential risks that infection with the Zika virus might pose for pregnancies in which the mother is also infected with HIV. At this point, little is known about whether Zika virus...read more
Poster: Addressing a Critical Shortage in the HIV Workforce: Design and Evaluation of an Interdisciplinary HIV Student Symposium
By: Elizabeth M. Sherman, PharmD, AAHIVP; Maia Goldenberg; Marylee V. Wormley, PharmD, BCPS; Mark Schweizer, DDS; Jose Castro, MD; Ana Garcia, PhD; Silvia Rabionet, EdD Background: Growing deficit of providers specializing in HIV/AIDS stymies efforts to improve care...read more
Presented By: Anna Person, MD Click Here To Download Presentation Presented By: Amen Eguakun, FNP-BC, AAHIVS Click Here To Download Presentation Presented By: Cody Chastain, MD Click Here To Download Presentation Presented By: Steve Raffanti, MD, MPH Click Here To...read more
FDA HIV Update: Approval of Generic Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg
Cross-posted from FDA Office of Health and Constituent Affairs Editor's Note: Generic drug approval by the FDA allows the generic drug to be marketed in the United States. The manufacturer determines when they will launch the product for marketing. On June 8, 2017,...read more